Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: A case report

Oncology Research

Volumn 16, Issue 10, 2007, Pages 489-495

  Kijima, Takashi ^a   Suzuki, Mayumi ^a   Ueda, Kayo ^b   Minami, Seigo ^a   Takeda, Yoshito ^a   Goya, Sho ^a   Matsuoka, Hiroto ^a   Kumagai, Toru ^a   Yoshida, Mitsuhiro ^a   Osaki, Tadashi ^a   Tachibana, Isao ^a   Yokota, Soichiro ^b   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Acquired resistance; Bronchioloalveolar carcinoma; Epidermal growth factor receptor; Gefitinib; Re treatment; Short term treatment

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NAVELBINE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; LIVER TOXICITY; LUNG ALVEOLUS CELL CARCINOMA; PARONYCHIA; PRIORITY JOURNAL; RECEPTOR GENE; SHORT COURSE THERAPY; TREATMENT OUTCOME;

EID: 38149037840     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504007783338313     Document Type: Article

References (23)

1. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2237-2246; 2003.
2. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537; 2005.
3. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500; 2004.
4. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139; 2004.
5. Cappuzzo, F.; Hirsch, F. R.; Rossi, E.; Bartolini, S.; Ceresoli, G. L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W. A.; Crino, L.; Bunn, Jr., P. A.; Varella-Garcia, M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97:643-655; 2005.
6. Hirsch, F. R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A. C.; Gumerlock, P.; Bunn, Jr., P. A.; Franklin, W. A.; Crowley, J.; Gandara, D. R. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J. Clin. Oncol. 23:6838-6845; 2005.
7. Hirsch, F. R.; Varella-Garcia, M.; Bunn, Jr., P. A.; Franklin, W. A.; Dziadziuszko, R.; Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J. R.; Ciuleanu, T.; von Pawel, J.; Watkins, C.; Flannery, A.; Ellison, G.; Donald, E.; Knight, L.; Parums, D.; Botwood, N.; Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24:5034-5042; 2006.
8. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:786-792; 2005.
9. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73; 2005.
10. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:205-216; 2000.
11. Kurata, T.; Tamura, K.; Kaneda, H.; Nogami, T.; Uejima, H.; Asai Go, G.; Nakagawa, K.; Fukuoka, M. Effect of re-treatment with gefitinib ('Iressa,' ZD1839) after acquisition of resistance. Ann. Oncol. 15:173-174; 2004.
12. Yano, S.; Nakataki, E.; Ohtsuka, S.; Inayama, M.; Tomimoto, H.; Edakuni, N.; Kakiuchi, S.; Nishikubo, N.; Muguruma, H.; Sone, S. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: A report of three cases. Oncol. Res. 15:107-111; 2005.
13. Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I.; Kunitoh, H.; Shibata, T.; Sakiyama, T.; Yoshida, T.; Tamura, T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23:6829-6837; 2005.
14. Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23:2513-2520; 2005.
15. Sutani, A.; Nagai, Y.; Udagawa, K.; Uchida, Y.; Koyama, N.; Murayama, Y.; Tanaka, T.; Miyazawa, H.; Nagata, M.; Kanazawa, M.; Hagiwara, K.; Kobayashi, K. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer 95:1483-1489; 2006.
16. Nagai, Y.; Miyazawa, H.; Huqun; Tanaka, T.; Udagawa, K.; Kato, M.; Fukuyama, S.; Yokote, A.; Kobayashi, K.; Kanazawa, M.; Hagiwara, K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276-7282; 2005.
17. Kris, M. G.; Sandler, A.; Miller, V.; Cepson, M.; Zakowski, M.; Pizzo, B.; Venkatraman, E.; Gomez, J.; Johnson, D.; Carbone, D. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc. Am. Soc. Clin. Oncol. 22:7062; 2004.
18. Kris, M. G.; Sandler, A.; Miller, V. A.; Zakowski, M. F.; Pao, W.; Tsao, A.; Patel, J. D.; Johnson, D. H.; Carbone, D. P. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. Proc. Am. Soc. Clin. Oncol. 23:7029; 2005.
19. Marchetti, A.; Martella, C.; Felicioni, L.; Barassi, F.; Salvatore, S.; Chella, A.; Camplese, P. P.; Iarussi, T.; Mucilli, F.; Mezzetti, A.; Cuccurullo, F.; Sacco, R.; Buttitta, F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23:857-865; 2005.
20. Gumerlock, P. H.; Holland, W. S.; Chen, H.; Franklin, W. A.; Hirsch, F. R.; Mack, P. C.; Davies, A. M.; McCoy, J.; West, H. J.; Gandara, D. R. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioloalveolar carcinoma (BAC) patients (pts) treated with gefitinib. Proc. Am. Soc. Clin. Oncol. 23:7008; 2005.
21. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102:7665-7670; 2005.
22. Nakatomi, K.; Soda, H.; Kitazaki, T.; Nakano, H.; Uchida, K.; Urabe, S.; Nakamura, Y.; Hayashi, T.; Tsukamoto, K.; Kohno, S. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 52:253-255; 2006.
23. Choong, N. W.; Dietrich, S.; Seiwert, T. Y.; Tretiakova, M. S.; Nallasura, V.; Davies, G. C.; Lipkowitz, S.; Husain, A. N.; Salgia, R.; Ma, P. C. Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat. Clin. Pract. Oncol. 3:50-57; 2006.